SB1114: Expanding Access to Low-Cost Generics Act of 2023
- 1Introduced (current step)
- 2Passed One Chamber
- 3Passed Both Chambers
- 4Became Law
Here is how to read this bill
Start with the summary
It says what the bill does in plain language. The official text is one tab over.
Check where it is
The status badge says how far it has gotten. The History tab lists every step.
Follow it
We will email you when it moves. You need a free account.
Tell someone who votes on it
Email or call the sponsor, or find your own representatives, from the actions panel.
Bill information
Summary
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period.
Plain-language summary
This bill would change the 180-day exclusivity period in federal drug law—a period that currently gives one generic drug maker a temporary advantage over competitors after a brand-name drug's patent expires. The bill aims to make generic medications more affordable and accessible to consumers. It modifies rules under the Federal Food, Drug, and Cosmetic Act, which governs how drugs are approved and sold in the United States. The bill is currently in the introduction stage and has not yet been assigned to a for formal review.
AI-generated summary
What can I do?
It's early in the process — messages to the sponsor and your representatives carry the most weight right now.
Contact Your Representatives
Calling or emailing is the most direct way to weigh in — offices tally constituent contacts.
Find Your RepresentativesShare This Bill
Sharing helps others in your district get informed and involved.
SB1114: Expanding Access to Low-Cost Generics Act of 2023